FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310108046> ?p ?o ?g. }

• W4310108046 endingPage "5568" @default.
• W4310108046 startingPage "5567" @default.
• W4310108046 abstract "Introduction: Immune thrombocytopenia (ITP) is an acquired, organ-specific, autoimmune disease and one of the most common bleeding disorders that seriously endangers human health. Iguratimod is a small molecule compound that is widely used as a novel antirheumatic drug in the treatment of rheumatoid arthritis in China and Japan. Iguratimod inhibits the production of several inflammatory cytokines, including IL-1, IL-6, IL-8, and tumor necrosis factor (TNF), and reduces the production of immunoglobulins. Th1 and Th17 cell counts were significantly reduced in patients with rheumatoid arthritis after treatment with iguratimod. The low long-term remission rate of ITP makes the investigation of its pathogenesis and the search for new treatments important clinical problems to be solved. Abnormal T-cell function and anti-platelet antibody production play important roles in the pathogenesis of ITP, and iguratimod is a therapeutic agent that could potentially be used to treat ITP. Previous clinical studies have shown that iguratimod can increase platelet levels in patients with dry syndrome. The potential of iguratimod for treating anti-platelet antibody-mediated thrombocytopenia in mice with ITP by modulating T-cell differentiation suggests that iguratimod may be a new approach for the prevention and treatment of ITP. Recent retrospective clinical studies and case reports have also shown that the use of iguratimod in autoimmune diseases is associated with good safety and efficacy. In conclusion, the aim of this study was to investigate the effect of iguratimod on the treatment of ITP. Methods: The study began in December 2020 and is ongoing. A total of 76 patients who were treated with iguratimod for at least 3 months were selected. Of these, 51 patients were treated for more than 6 months, and 30 patients were treated for at least 12 months. Five patients withdrew from observation after 3 months: two patients due to NR, three patients due to epidemic and financial reasons, and no patients due to AE. Key secondary endpoints included initial response by Day 14 (OR, platelet count ≥30×109/L, at least a 2-fold increase in baseline platelet count, and absence of bleeding; and CR, platelet count ≥ 100×109/L), duration of response, bleeding scores, and adverse events (AEs). This study was registered with ClinicalTrials.gov (). Results: At baseline, 73.5% of the patients reported symptoms of grade 1 to 4 bleeding. After 3 months of treatment, the proportion of patients with any bleeding symptoms decreased to 61.8% and remained below baseline throughout the study period. At baseline, 63 patients reported the use of concomitant medications, which decreased by 36.5% between 3 and 6 months. The most frequently discontinued or reduced medications were glucocorticoids and rituximab. All the patients took the medication in strict accordance with the instructions and medical advice. The patients were monitored monthly to assess blood, liver, kidney function, and no abnormalities in laboratory tests, such as elevated transaminases or lymphocytopenia, were observed. Conclusions: Iguratimod has good efficacy and safety in the treatment of ITP and has the potential to become a new treatment for ITP." @default.
• W4310108046 created "2022-11-30" @default.
• W4310108046 creator A5001508669 @default.
• W4310108046 creator A5002188808 @default.
• W4310108046 creator A5011029344 @default.
• W4310108046 creator A5013296641 @default.
• W4310108046 creator A5018709756 @default.
• W4310108046 creator A5035514027 @default.
• W4310108046 creator A5046348283 @default.
• W4310108046 creator A5046424825 @default.
• W4310108046 creator A5046756784 @default.
• W4310108046 creator A5047932271 @default.
• W4310108046 creator A5051211027 @default.
• W4310108046 creator A5054252496 @default.
• W4310108046 creator A5065894155 @default.
• W4310108046 creator A5068526324 @default.
• W4310108046 creator A5071362089 @default.
• W4310108046 creator A5072028717 @default.
• W4310108046 creator A5072208411 @default.
• W4310108046 creator A5078632164 @default.
• W4310108046 creator A5087610827 @default.
• W4310108046 creator A5088505823 @default.
• W4310108046 date "2022-11-15" @default.
• W4310108046 modified "2023-09-27" @default.
• W4310108046 title "Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP" @default.
• W4310108046 doi "https://doi.org/10.1182/blood-2022-167362" @default.
• W4310108046 hasPublicationYear "2022" @default.
• W4310108046 type Work @default.
• W4310108046 citedByCount "0" @default.
• W4310108046 crossrefType "journal-article" @default.
• W4310108046 hasAuthorship W4310108046A5001508669 @default.
• W4310108046 hasAuthorship W4310108046A5002188808 @default.
• W4310108046 hasAuthorship W4310108046A5011029344 @default.
• W4310108046 hasAuthorship W4310108046A5013296641 @default.
• W4310108046 hasAuthorship W4310108046A5018709756 @default.
• W4310108046 hasAuthorship W4310108046A5035514027 @default.
• W4310108046 hasAuthorship W4310108046A5046348283 @default.
• W4310108046 hasAuthorship W4310108046A5046424825 @default.
• W4310108046 hasAuthorship W4310108046A5046756784 @default.
• W4310108046 hasAuthorship W4310108046A5047932271 @default.
• W4310108046 hasAuthorship W4310108046A5051211027 @default.
• W4310108046 hasAuthorship W4310108046A5054252496 @default.
• W4310108046 hasAuthorship W4310108046A5065894155 @default.
• W4310108046 hasAuthorship W4310108046A5068526324 @default.
• W4310108046 hasAuthorship W4310108046A5071362089 @default.
• W4310108046 hasAuthorship W4310108046A5072028717 @default.
• W4310108046 hasAuthorship W4310108046A5072208411 @default.
• W4310108046 hasAuthorship W4310108046A5078632164 @default.
• W4310108046 hasAuthorship W4310108046A5087610827 @default.
• W4310108046 hasAuthorship W4310108046A5088505823 @default.
• W4310108046 hasBestOaLocation W43101080461 @default.
• W4310108046 hasConcept C126322002 @default.
• W4310108046 hasConcept C142424586 @default.
• W4310108046 hasConcept C177713679 @default.
• W4310108046 hasConcept C191897082 @default.
• W4310108046 hasConcept C192562407 @default.
• W4310108046 hasConcept C71924100 @default.
• W4310108046 hasConceptScore W4310108046C126322002 @default.
• W4310108046 hasConceptScore W4310108046C142424586 @default.
• W4310108046 hasConceptScore W4310108046C177713679 @default.
• W4310108046 hasConceptScore W4310108046C191897082 @default.
• W4310108046 hasConceptScore W4310108046C192562407 @default.
• W4310108046 hasConceptScore W4310108046C71924100 @default.
• W4310108046 hasIssue "Supplement 1" @default.
• W4310108046 hasLocation W43101080461 @default.
• W4310108046 hasOpenAccess W4310108046 @default.
• W4310108046 hasPrimaryLocation W43101080461 @default.
• W4310108046 hasRelatedWork W2068316626 @default.
• W4310108046 hasRelatedWork W2110818089 @default.
• W4310108046 hasRelatedWork W2351796763 @default.
• W4310108046 hasRelatedWork W2351985199 @default.
• W4310108046 hasRelatedWork W2403502999 @default.
• W4310108046 hasRelatedWork W2528057197 @default.
• W4310108046 hasRelatedWork W2567738959 @default.
• W4310108046 hasRelatedWork W2789412726 @default.
• W4310108046 hasRelatedWork W4297834875 @default.
• W4310108046 hasRelatedWork W4366141624 @default.
• W4310108046 hasVolume "140" @default.
• W4310108046 isParatext "false" @default.
• W4310108046 isRetracted "false" @default.
• W4310108046 workType "article" @default.